“The apprehension with employing non IID stated ingredients is justified as it is actually difficult To guage if FDA would find the ‘novel excipient’ Protected to be used in the drug product as there is no outlined approach for evaluation and approval of excipients. The FDA guidance on ‘Nonclinical https://lutherz136pqc8.ja-blog.com/profile